<DOC>
	<DOCNO>NCT02268383</DOCNO>
	<brief_summary>Study A536-05 open-label extension study patient previously enrol study A536-03 ( ClinicalTrials.gov Identifier NCT01749514 ) , evaluate long-term safety tolerability ACE-536 patient low intermediate-1 risk MDS .</brief_summary>
	<brief_title>ACE-536 Extension Study - Myelodysplastic Syndromes</brief_title>
	<detailed_description>Study A536-05 open-label extension study evaluate safety , tolerability , pharmacodynamic effect 24 month ACE-536 treatment patient low intermediate-1 risk myelodysplastic syndrome previously treat ACE-536 3 month study A536-03 ( ClinicalTrials.gov Identifier NCT01749514 ) . The start dose level study A536-05 1.0 mg/kg subcutaneous ( SC ) injection every 3 week . Dose titration/modification rule follow individual patient base upon safety efficacy data collect course treatment .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Completion treatment period base study A53603 ( ClinicalTrials.gov Identifier : NCT01749514 ) Adequate birth control measure Patient able adhere study visit schedule , understand comply protocol requirement . Patient understand able provide write informed consent . In addition , patient treatment interruption ( defined patient complete endofstudy visit A53603 directly roll A53605 ) must also meet follow criterion : Documented diagnosis idiopathic/de novo MDS nonproliferative chronic myelomonocytic leukemia ( CMML ) accord World Health Organization ( WHO ) criteria 2 ( white blood count ( WBC ) &lt; 13,000/μL ) meet International Prognostic Scoring System ( IPSS ) classification ( Appendix 2 ) low intermediate1 risk disease determine microscopic standard cytogenetic analysis bone marrow peripheral complete blood count ( CBC ) obtain screen ; Anemia define : Mean hemoglobin concentration &lt; 10.0 g/dL 2 measurement ( one perform within one day prior Cycle 1 Day 1 perform 728 day prior Cycle 1 Day 1 ) , nontransfusion dependent ( NTD ) patient ( define receive ˂ 4 unit red blood cell ( RBCs ) within 8 week prior Cycle 1 Day 1 ) , OR Transfusion Dependent ( TD ) , define receive ≥ 4 unit RBCs within 8 week prior Cycle 1 Day 1 . Platelet count ≥ 30 x 109/L Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 ( related anemia ) Adequate renal ( creatinine ≤ 2.0 x upper limit normal [ ULN ] ) hepatic ( total bilirubin &lt; 2 x ULN aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 3 x ULN ) function Discontinuation/withdrawal base study A53603 ( due patient request , patient unwillingness inability comply protocol , pregnancy , use prohibit medication [ e.g . azacitidine ] , medical reason adverse event ( AE ) , hypersensitivity reaction study drug , discretion sponsor , loss followup ) prior completion treatment period Prior treatment azacitidine decitabine Treatment within 28 day prior Cycle 1 Day 1 : erythropoiesisstimulating agent ( ESA ) , Granulocyte colonystimulating factor ( GCSF ) granulocytemacrophage colony stimulate factor ( GMCSF ) , Lenalidomide Iron chelation therapy initiate within 56 day prior Cycle 1 Day 1 Treatment another investigational drug ( include sotatercept [ ACE011 ] ) device , approve therapy investigational use ≤ 28 day prior Cycle 1 Day 1 , halflife previous investigational product know , within 5 time halflife prior Cycle 1 Day 1 , whichever long Major surgery within 28 day prior Cycle 1 Day 1 . Patients must completely recover previous surgery prior Cycle 1 Day 1 Known positive human immunodeficiency virus ( HIV ) , active infectious hepatitis B ( HBV ) active infectious hepatitis C ( HCV ) Uncontrolled hypertension define systolic blood pressure ( SBP ) ≥ 150 mm Hg diastolic blood pressure ( DBP ) ≥ 100 mm Hg Pregnant lactate female History severe allergic anaphylactic reaction hypersensitivity recombinant proteins excipients investigational drug Any condition specifically note , judgment investigator , would preclude patient participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>